The GlaxoSmithKline breast cancer drug Tykerb didn't improve survival rates for patients with advanced gastric cancer, the company announced Monday.
The British company, which has its U.S. headquarters in Research Triangle Park, was testing Tykberb in combination with chemotherapy to see if it would improve how long patients could live with gastric cancer and how long they could keep the disease from progressing.
But according to the company, the treatment did not meet its goals of overall survival when compared to chemotherapy alone during phase III trials.
The drug, lapatinib, is marketed as Tykerb in the United States and Tyverb in Europe.
Tykerb was developed by GSK scientists in RTP, and approved as a treatment for breast cancer in 2007.